{
    "organizations": [],
    "uuid": "96f9b85c793c3b9f11f7436aff54cff3295efd27",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ab-science-announces-negative-opin/brief-ab-science-announces-negative-opinion-from-chmp-idUSFWN1RW0VA",
    "ord_in_thread": 0,
    "title": "BRIEF-AB Science Announces Negative Opinion From CHMP",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - AB SCIENCE SA:\n* REG-AB SCIENCE ANNOUNCES THAT THE CHMP HAS ADOPTED A NEGATIVE OPINION FOR THE MARKETING AUTHORIZATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS\n* AB SCIENCE WILL PROVIDE ADDITIONAL DATA THROUGH A REEXAMINATION PROCEDURE\n* RE-EXAMINATION WILL LEAD CHMP TO DELIVER A SECOND OPINION IN JULY 2018\n* REAFFIRMS ITS COMMITMENT TO CARRY OUT DEVELOPMENT OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)\n ",
    "published": "2018-04-20T01:18:00.000+03:00",
    "crawled": "2018-04-20T12:18:00.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "ab",
        "science",
        "sa",
        "science",
        "announces",
        "chmp",
        "adopted",
        "negative",
        "opinion",
        "marketing",
        "authorization",
        "masitinib",
        "amyotrophic",
        "lateral",
        "sclerosis",
        "ab",
        "science",
        "provide",
        "additional",
        "data",
        "reexamination",
        "procedure",
        "lead",
        "chmp",
        "deliver",
        "second",
        "opinion",
        "july",
        "reaffirms",
        "commitment",
        "carry",
        "development",
        "masitinib",
        "amyotrophic",
        "lateral",
        "sclerosis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}